| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Kane Biotech Inc (2): Kane publishes clinical study in Int'l Wound Journal | 1 | Stockwatch | ||
| KANE BIOTECH Aktie jetzt für 0€ handeln | |||||
| 04.11. | Kane Biotech Inc.: Kane Announces Publication of Real-World Evidence in the International Wound Journal | 3 | GlobeNewswire (USA) | ||
| 22.10. | Kane Biotech Inc (2): Kane Biotech hires ITG for market-making services | 2 | Stockwatch | ||
| 21.10. | Kane Biotech Inc.: Kane Engages Independent Trading Group as Market Maker | 1 | GlobeNewswire (USA) | ||
| 20.10. | Kane Biotech Inc (2): Kane Biotech signs Stevens as Canadian distributor | 1 | Stockwatch | ||
| 20.10. | Kane Biotech signs distribution deal with Stevens Company | 1 | Investing.com | ||
| 20.10. | Kane Biotech Inc.: Kane Biotech Signs Distribution Agreement with The Stevens Company | 4 | GlobeNewswire (USA) | ||
| 19.10. | Kane Biotech Inc.: Kane Launches New Corporate Brand and Redesigned Website | 1 | GlobeNewswire (USA) | ||
| 16.10. | Kane Biotech Inc (2): Kane Biotech gets insider loan to keep the lights on | 1 | Stockwatch | ||
| 16.10. | Kane Biotech Inc.: Kane Biotech Announces $250,000 Insider Loan | 1 | GlobeNewswire (USA) | ||
| 07.10. | Kane Biotech Inc.: Kane Biotech to Present Clinical Data and Showcase revyve Product Line at SAWC Fall 2026 | 2 | GlobeNewswire (USA) | ||
| 09.09. | Kane Biotech Inc (2): Kane Biotech to host commercial update webcast Sept. 16 | 1 | Stockwatch | ||
| 09.09. | Kane Biotech Inc.: Kane Biotech to Host Commercial Update Webcast on September 16 | 1 | GlobeNewswire (USA) | ||
| 02.09. | Kane Biotech Inc.: Kane Biotech Expands Canadian Commercial Reach with Ontario Medical Supply Inc. | 204 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Company", "Kane" or "Kane Biotech") is pleased to announce that it has entered into a non-exclusive distribution... ► Artikel lesen | |
| 27.08. | Kane Biotech Inc.: Kane Biotech Announces Second Quarter 2026 Financial Results | 426 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Company", "Kane" or "Kane Biotech") announces today its second quarter 2026 financial results. Second Quarter... ► Artikel lesen | |
| 05.08. | Kane Biotech Inc (2): Kane Biotech hires DNA Advisors as financial adviser | 1 | Stockwatch | ||
| 05.08. | Kane Biotech Inc.: Kane Biotech Announces Engagement of DNA Advisors | 389 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) ("Kane" or the "Company"), announces that it has retained DNA Advisors Inc. ("DNA Advisors") as its exclusive financial... ► Artikel lesen | |
| 02.07. | Kane Biotech Inc (2): Kane Biotech shareholders approve matters at meeting | 1 | Stockwatch | ||
| 02.07. | Kane Biotech Inc.: Kane Biotech Announces Results of Annual and Special Meeting of Shareholders | 275 | GlobeNewswire (Europe) | WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the "Company", "Kane" or "Kane Biotech") the voting results from its annual and special meeting of shareholders... ► Artikel lesen | |
| 30.05. | Kane Biotech Inc (2): Kane Biotech grants options to buy 9.75 million shares | 5 | Stockwatch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,325 | -4,68 % | NanoRepro: NuWays bleibt bei Kaufen - Paedi Protect läuft stärker als gedacht | ||
| PALATIN TECHNOLOGIES | 5,260 | 0,00 % | Earnings Call: Palatin Technologies verfehlt Markterwartungen deutlich - Aktie bricht um 14 % ein | ||
| BRAIN BIOTECH | 2,490 | -0,80 % | BRAIN Biotech und Syngenta kooperieren bei biologischem Pflanzenschutz | BRAIN Biotech hat mit dem Agrarkonzern Syngenta eine strategische Zusammenarbeit zur Entwicklung biologischer Pflanzenschutzlösungen vereinbart. Im Mittelpunkt steht der Einsatz synthetischer Biologie... ► Artikel lesen | |
| AAP IMPLANTATE | 1,360 | -6,21 % | aap Implantate - Aktie vor Neubewertung? CEO und COO im Interview: "Die Basis steht, jetzt schalten wir auf Wachstum." | Eine spannende Sondersituation zeichnet sich derzeit bei der aap Implantate AG (ISIN: DE000A3H2101) ab: Nach Jahren der Restrukturierung und hohen regulatorischen Aufwendungen hat der Berliner Spezialist... ► Artikel lesen | |
| CO.DON | 0,005 | -16,67 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| CLINUVEL | 4,413 | -6,54 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| BIO-GATE | 2,180 | -3,54 % | Original-Research: Bio-Gate AG (von BankM AG): Kaufen | Original-Research: Bio-Gate AG - von BankM AG
10.11.2026 / 12:44 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,000 | 0,00 % | COSCIENS Biopharma Inc. Q3 Loss Widens | ||
| EDITAS MEDICINE | 1,650 | -2,65 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| EXELIXIS | 62,01 | +1,61 % | Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | ||
| EVONEXT | 2,460 | -1,60 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26 | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26
16-Nov-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| GERON | 0,895 | +4,41 % | Geron auf der Stifel Healthcare Conference 2026: RYTELO gewinnt an Dynamik | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |